Active Ingredient History

  • Now
Vosaroxin is a topoisomerase II inhibitor causing site-selective DNA damage. It is under phase III clinical trial investigation for acute myelogenous leukemia (AML) and ovarian cancer sponsored by Sunesis.   Wikipedia

  • SMILES: CN[C@H]1CN(C[C@@H]1OC)c2ccc3C(=O)C(=CN(c4nccs4)c3n2)C(=O)O
  • Mol. Mass: 401.45
  • ALogP: 0.96
  • ChEMBL Molecule:
More Chemistry
1,4-dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | ag7352 | ag 7352 | ag-7352 | sns-595 | voreloxin | vosaroxin


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue